Zim Laboratories Ltd
NSE: ZIMLAB BSE: 541400
₹73.30
(2.53%)
Thu, 16 Apr 2026, 06:06 pm
Market Cap3.41B
PE Ratio51.16
Dividend0
Health Technology
Pharmaceuticals: Generic
24.5KZim Laboratories Analysis
dividend
- Dividends paid are well covered by earnings (4.1x coverage).
- ZIM Laboratories has only been paying a dividend for 2 years, and since then there has been no growth.
- Whilst dividend payments have been stable, ZIM Laboratories has been paying a dividend for less than 10 years.
- ZIM Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- ZIM Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- ZIM Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- ZIM Laboratories is profitable, therefore cash runway is not a concern.
- ZIM Laboratories is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (28.4%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 2.4x debt.
- ZIM Laboratories's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (98.7% vs 50.1% today).
- Interest payments on debt are not well covered by earnings (EBIT is 0.6x annual interest expense, ideally 3x coverage).
- ZIM Laboratories's level of debt (50.1%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The tenure for the ZIM Laboratories board of directors is about average.
- Anwar's remuneration is lower than average for companies of similar size in India.
misc
- ZIM Laboratories is not covered by any analysts.
- ZIM Laboratories has significant price volatility in the past 3 months.
past
- ZIM Laboratories has delivered over 20% year on year earnings growth in the past 5 years.
- ZIM Laboratories's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- ZIM Laboratories used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- ZIM Laboratories's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- ZIM Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- ZIM Laboratories's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- ZIM Laboratories is good value based on assets compared to the IN Pharmaceuticals industry average.
- BSE:541400 is up 6.3% along with the Pharmaceuticals industry (6.8%) over the past month.
- ZIM Laboratories's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- ZIM Laboratories's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- ZIM Laboratories is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- ZIM Laboratories is overvalued based on earnings compared to the India market.
- 541400 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 541400 underperformed the Market in India which returned -14.5% over the past year.
- BSE:541400 is up 6.3% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800